184 related articles for article (PubMed ID: 36045270)
1. Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer.
Kwon SS; Nam BD; Lee MY; Lee MH; Lee J; Park BW; Bang DW; Kwon SH
Breast Cancer Res Treat; 2022 Nov; 196(1):111-119. PubMed ID: 36045270
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis.
Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW; Madurawe RD; Sathananthan PP; Ekanayake U; Horadugoda J
Biomed Res Int; 2020; 2020():1847159. PubMed ID: 33274195
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
4. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
5. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ
Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467
[TBL] [Abstract][Full Text] [Related]
6. Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy.
Jin CL; Shi XG; Wang TT; Li HW; Zhang DX; Sheng Z; Xiao J; Yu YQ
BMC Cardiovasc Disord; 2023 Sep; 23(1):465. PubMed ID: 37715125
[TBL] [Abstract][Full Text] [Related]
7. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.
Santoro C; Arpino G; Esposito R; Lembo M; Paciolla I; Cardalesi C; de Simone G; Trimarco B; De Placido S; Galderisi M
Eur Heart J Cardiovasc Imaging; 2017 May; 18(8):930-936. PubMed ID: 28379383
[TBL] [Abstract][Full Text] [Related]
8. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.
Foulkes SJ; Howden EJ; Haykowsky MJ; Antill Y; Salim A; Nightingale SS; Loi S; Claus P; Janssens K; Mitchell AM; Wright L; Costello BT; Lindqvist A; Burnham L; Wallace I; Daly RM; Fraser SF; La Gerche A
Circulation; 2023 Feb; 147(7):532-545. PubMed ID: 36342348
[TBL] [Abstract][Full Text] [Related]
9. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
[TBL] [Abstract][Full Text] [Related]
10. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
12. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
14. The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients.
Inanc MT; Karadavut S; Aytekin M; Duran AO; Derya M; Akpek M; Sahin O; Kalay N; Karaca H; Ozkan M; Inanc M
Int J Cardiol; 2016 Sep; 218():246-251. PubMed ID: 27236123
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
17. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial.
Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Capela A; Amarelo A; Marques C; Viamonte S; Alves A; Esteves D
Eur J Prev Cardiol; 2023 Jul; 30(9):844-855. PubMed ID: 36857149
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
20. Changes in epicardial adipose tissue among women treated with trastuzumab for breast cancer.
Li W; Liu M; Yu F; Jiang T; Zhu W; Liu H
Int J Cardiol; 2022 Feb; 348():163-168. PubMed ID: 34890762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
